- Home
- MDCX vs KTTA Comparison
MDCX vs KTTA Comparison
Compare MDCX & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDCX
- KTTA
- Stock Information
- Founded
- MDCX 2008
- KTTA 2020
- Country
- MDCX Canada
- KTTA United States
- Employees
- MDCX N/A
- KTTA N/A
- Industry
- MDCX
- KTTA Biotechnology: Pharmaceutical Preparations
- Sector
- MDCX
- KTTA Health Care
- Exchange
- MDCX Nasdaq
- KTTA Nasdaq
- Market Cap
- MDCX 44.0M
- KTTA 5.5M
- IPO Year
- MDCX N/A
- KTTA 2021
- Fundamental
- Price
- MDCX $3.07
- KTTA $0.67
- Analyst Decision
- MDCX Strong Buy
- KTTA
- Analyst Count
- MDCX 2
- KTTA 0
- Target Price
- MDCX $23.50
- KTTA N/A
- AVG Volume (30 Days)
- MDCX 482.2K
- KTTA 142.8K
- Earning Date
- MDCX 08-22-2025
- KTTA 08-12-2025
- Dividend Yield
- MDCX N/A
- KTTA N/A
- EPS Growth
- MDCX N/A
- KTTA N/A
- EPS
- MDCX N/A
- KTTA N/A
- Revenue
- MDCX N/A
- KTTA N/A
- Revenue This Year
- MDCX N/A
- KTTA N/A
- Revenue Next Year
- MDCX N/A
- KTTA N/A
- P/E Ratio
- MDCX N/A
- KTTA N/A
- Revenue Growth
- MDCX N/A
- KTTA N/A
- 52 Week Low
- MDCX $1.80
- KTTA $0.67
- 52 Week High
- MDCX $8.94
- KTTA $7.50
- Technical
- Relative Strength Index (RSI)
- MDCX N/A
- KTTA 32.03
- Support Level
- MDCX N/A
- KTTA $0.68
- Resistance Level
- MDCX N/A
- KTTA $0.77
- Average True Range (ATR)
- MDCX 0.00
- KTTA 0.03
- MACD
- MDCX 0.00
- KTTA 0.01
- Stochastic Oscillator
- MDCX 0.00
- KTTA 13.04
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).